Trial Profile
A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, Immunogenicity, Pharmacodynamic Response, and Pharmacokinetics of Intravenous Infusions of BAN2401 in Subjects With Mild to Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Nov 2020
Price :
$35
*
At a glance
- Drugs Lecanemab (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Eisai Inc
- 17 Jul 2013 Results presented at the 2013 Alzheimer's Association International Conference .
- 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Dec 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.